A reputed Indian beauty & personal care company developed a herbal skin cream for the international market, claiming anti-ageing and skin-repair properties based on traditional Ayurvedic formulations. After obtaining the necessary approvals and export certifications, the company began exporting the product. The product received widespread positive feedback for its quality and natural formulation, and soon became a huge hit in international markets. Riding on this success, the company announced that the product would soon be made available to domestic consumers, with almost the same quality and health benefits. Subsequently, it secured approval from the domestic regulatory authority and launched the product in the Indian market. Over time, the brand gained a significant share of the domestic market and earned substantial revenues both nationally and internationally. However, during a random sample check, officials discovered that the cream sold in India differed from the version approved by the competent authority. The product failed to meet the claimed herbal composition and purity standards. Further investigation revealed that the company had often been distributing batches that had failed export quality checks. The incident triggered widespread public criticism and regulatory scrutiny, leading to a sharp decline in the company's reputation and financial performance. a) Discuss the ethical issues involved in the case. b) What actions should the competent regulatory authority take against the personal care company for violating domestic quality standards and distributing rejected export batches in the Indian market? c) What course of action is available to the company to manage the crisis and restore public trust and brand credibility?
Deepali Mahto, AIR 36, 2025
This case study reflects the double standards that companies adopt to bypass checking standards, due to laxity in laws in India.
a) The ethical issues involved are: 1. Lack of upholding rigorous checks - objectivity & integrity are compromised. 2. Breaching of social trust and contract (John Rawls). 3. Against the Drugs and Cosmetics Act. 4. Use of unethical means to achieve profit (crony capitalism). 5. Bypassing safety regulations showcases collusive corruption. 6. Using rejected materials in Indian markets - shows profit without principle. 7. Engaging in false advertisements - against deontological ethics.
b) The competent authority should take the following actions:
Short term: 1. Suspension of the company's functioning till the investigation is complete. 2. Investigation that upholds data, laws and regulations (objectivity) - to showcase the law by upholding of the Drugs and Cosmetics Act, use of third-party lab testing. 3. Booking the company under the necessary sections of BNS, BSS. 4. To show transparency, the investigation agency should release the report in the public domain ("justice should not be done, but also seen to be done") - reduces apprehension and false news. 5. Recall the products in the market (to reduce further damage).
Long term: 1. Stringent regulation should be followed. 2. Promote flow of data between the Central Drug Authority & State Drug Standards Authority. 3. Regular check-ups to check any malfunction.
c) The course of action for the company: 1. The company should recall the defective materials. 2. Release a press release stating its malpractices and apologise for its behaviour (shows accountability). 3. Support the investigation agency in its functioning. 4. Install an internal audit to check the internal cause (shows integrity, objectivity).
Long term: 1. Regular release of drug trial data. 2. Positive advertisements to showcase transparency. 3. CSR initiative to instill trust.
By doing the above actions the company can overcome the challenges as well as uphold the trusteeship principle of Gandhiji.